BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Friday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOLASE Price Performance

BIOLASE stock opened at $0.15 on Friday. The company has a 50-day simple moving average of $0.15 and a 200-day simple moving average of $0.83. The firm has a market capitalization of $4.81 million, a P/E ratio of 0.00 and a beta of 0.67. The company has a debt-to-equity ratio of 34.06, a quick ratio of 0.68 and a current ratio of 1.26. BIOLASE has a one year low of $0.13 and a one year high of $32.09.

BIOLASE (NASDAQ:BIOL) last released its quarterly earnings results on Thursday, March 21st. The medical technology company reported ($1.76) EPS for the quarter. The firm had revenue of $13.49 million for the quarter. BIOLASE had a negative return on equity of 555.22% and a negative net margin of 41.97%.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.